
Shoulder & Elbow
Recombinant human growth hormone injection does not improve healing rate versus control in RC repair
This report has been verified
by one or more authors of the
original publication.
J Shoulder Elbow Surg. 2018 May;27(5):777-785
91 patients scheduled for arthroscopic rotator cuff repair were randomized to either postoperative injections of weekly 4mg or 8mg recombinant human growth hormone (rhGH), or to a control with no postoperative injections. Patients were assessed for healing rate using the Sugaya classification, fatty infiltration and atrophy on MRI, and for clinical scores and range of motion over the first 6 months after surgery. Results demonstrated no significant differences between groups for any of the above outcome measures.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.